As­traZeneca, Mer­ck notch an­oth­er ma­jor Lyn­parza tri­al win — this time in pan­cre­at­ic can­cer

As­traZeneca and Mer­ck’s PARP in­hibitor Lyn­parza has chalked up an­oth­er land­mark win.

Months af­ter se­cur­ing a light­ning fast ap­proval for the use of the drug in front­line ovar­i­an can­cer — widen­ing their lead over the clus­ter of oth­er PARPs in­clud­ing Tesaro’s (now GSK’s) Ze­ju­la and Clo­vis’ Rubra­ca — Lyn­parza has shown promise in help­ing pa­tients with BR­CA-mu­tat­ed metasta­t­ic pan­cre­at­ic can­cer live longer with­out their can­cer pro­gress­ing in a late-stage study.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.